clinical protocol

Aknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Legal Notice

Cookies policy

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept all Reject

Tracking Cookies

Tracking Cookies

Third Party Embeds

YouTube
Facebook
Twitter

clinical protocol

D3.1 Design clinical protocol with WP4 partners to optimise patient recruitment and sampling for biomarker validation

Tags

Aknowledgement

Tracking Cookies

Third Party Embeds

clinical protocol

Share this tag

D3.1 Design clinical protocol with WP4 partners to optimise patient recruitment and sampling for biomarker validation

Tags

Aknowledgement

Tracking Cookies

Third Party Embeds